Spero Therapeutics, Inc. (SPRO)
Oxford Ledge is still expanding full research coverage of SPRO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biopharmaceutical company developing tebipenem HBr, an oral carbapenem for treating complicated urinary tract infections, licensed to GSK.
SEC filings
- 8-K Entry into material agreement; Creation of direct financial obligation; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-07-14
- 8-K Departure/election of directors or officers; Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-06-25
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-22
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-13
Source: SEC EDGAR.
Annual results
5 years of annual figures for SPRO, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $66.8M | $8.6M | $0.15 |
| 2024 | $48.0M | -$68.6M | -$1.27 |
| 2023 | $103.8M | $22.8M | $0.43 |
| 2022 | $53.5M | $46.4M | -$1.23 |
| 2021 | $18.3M | -$89.8M | -$2.91 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for SPRO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SPRO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.